The goal of this study is to better understand how an amylopectin chromium blend may influence whole body protein balance in women during midlife, when hormonal changes can adversely affect protein metabolism and muscle maintenance. Continuous glucose monitoring will also be used to assess glycemic control over a 24-hour period.
The main questions the study aims to answer are:
* Does the use of an amylopectin chromium blend in peri- and post-menopausal women help to support positive protein balance * Can the affect be achieved using a concentrated dose
Researchers will compare the nutritional supplement to a placebo (amylopectin alone) to see if the amylopectin chromium blend can promote positive protein balance. A concentrated dose of the supplement will also be evaluated for comparative effectiveness.
Participants will:
* Consume the nutritional supplement (standard or concentrated dose) or placebo acutely after a short resistance exercise bout * Complete four in-person visits, including the single-day intervention
Results from this research may help guide future nutritional strategies to support healthy aging, muscle function, and overall metabolic health.
≥ 60 days but < 12 months of amenorrhea (late perimenopause)
Women with ≥ 12 months of spontaneous amenorrhea (post-menopausal)
No more than 3 days per week of structured physical activity
Provide voluntary signed and dated informed consent.
Current use of any dietary ingredient that impacts glucose control or insulin sensitivity.
Current vegans or vegetarians.
Intolerance to dairy foods/drinks.
Smokes more than 10 cigarettes per day or uses other nicotine products (i.e. vape, patch) that deliver a similar amount of nicotine.
Nutrition 21, Inc.
Lead sponsor
The Center for Applied Health Sciences, LLC
Collaborator